Topline Results from Phase 2b Clinical Trial of UBX1325 for DME Expected in Q1 2025

The phase 2b study, known as ASPIRE, is currently in progress, focusing on the efficacy and safety of UBX1325 for the treatment of diabetic macular edema (DME). This clinical trial is a significant step forward in the development of new therapies for DME, a condition that affects a substantial number of individuals worldwide. The topline results from this study are eagerly awaited and are expected to be released in the first quarter of 2025. These results will provide valuable insights into the potential of UBX1325 as a treatment option for patients suffering from DME, marking a critical milestone in the ongoing efforts to address this challenging eye condition.